Faculty profile
Jessica Kalra
Back to facultyResearch
Read how they describe their research on their University of British Columbia profile.
Latest papers
Comparing the Utility of Cannabidiol Quantitation Methods for Use in High-Throughput In Vitro Assays.
ACS omega · 2026 · senior author
Accumulation of liposomes in metastatic tumor sites is not necessary for anti-cancer drug efficacy.
Journal of translational medicine · 2024 · first author
Inter-Metastatic Heterogeneity of Tumor Marker Expression and Microenvironment Architecture in a Preclinical Cancer Model.
International journal of molecular sciences · 2021 · first author
11 publications.
Comparing the Utility of Cannabidiol Quantitation Methods for Use in High-Throughput In Vitro Assays.
Alp G, Kermanshahi B, Olaizola A, Le Devedec F, Kalra J
Accumulation of liposomes in metastatic tumor sites is not necessary for anti-cancer drug efficacy.
Kalra J, Baker J, Sun X, Kyle A, Minchinton A, Bally MB
Inter-Metastatic Heterogeneity of Tumor Marker Expression and Microenvironment Architecture in a Preclinical Cancer Model.
Kalra J, Baker J, Song J, Kyle A, Minchinton A, Bally M
Multiplex Immunohistochemistry for Mapping the Tumor Microenvironment.
Kalra J, Baker J
Using Digital Quantification of Stained Tissue Microarrays as a Medium-Throughput, Quantitative Method for Measuring the Kinetics of Signal Transduction.
Kalra J, Baker J
Using Pharmacokinetic Profiles and Digital Quantification of Stained Tissue Microarrays as a Medium-Throughput, Quantitative Method for Measuring the Kinetics of Early Signaling Changes Following Integrin-Linked Kinase Inhibition in an In Vivo Model of Cancer.
Kalra J, Dragowska WH, Bally MB
5'-AMP-activated protein kinase (AMPK) supports the growth of aggressive experimental human breast cancer tumors.
Laderoute KR, Calaoagan JM, Chao WR, Dinh D, Denko N, Duellman S, Kalra J, Liu X, Papandreou I, Sambucetti L, Boros LG
Harnessing the potential of lipid-based nanomedicines for type-specific ovarian cancer treatments.
Leung AW, Kalra J, Santos ND, Bally MB, Anglesio MS
Validating the use of a luciferase labeled breast cancer cell line, MDA435LCC6, as a means to monitor tumor progression and to assess the therapeutic activity of an established anticancer drug, docetaxel (Dt) alone or in combination with the ILK inhibitor, QLT0267.
Kalra J, Anantha M, Warburton C, Waterhouse D, Yan H, Yang YJ, Strut D, Osooly M, Masin D, Bally MB
QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model.
Kalra J, Warburton C, Fang K, Edwards L, Daynard T, Waterhouse D, Dragowska W, Sutherland BW, Dedhar S, Gelmon K, Bally M
Frequent collaborators
- David Huntsman and Shoukat Dedhar: 2 shared papers
- Shoukat Dedhar and Marcel Bally: 2 shared papers
- Shoukat Dedhar and Jessica Kalra: 2 shared papers
- Andrew Minchinton and Marcel Bally: 2 shared papers
- Andrew Minchinton and Jessica Kalra: 2 shared papers
- Marcel Bally and Jessica Kalra: 2 shared papers
- David Huntsman and Andrew Minchinton: 1 shared paper
- David Huntsman and Marcel Bally: 1 shared paper
- David Huntsman and Jessica Kalra: 1 shared paper
- Pharmsci
- Experimental Therapeutics
- Biochemistry and Molecular Biology
- Molecular Oncology
- Other
Co-authors at University of British Columbia, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.
Profile data last refreshed on September 27, 2026 from the university directory, publication records and CIHR, NSERC and SSHRC funding.